Imagine if doctors could check the pressure inside your heart without needing to insert a needle or tube. This device works like a high-tech scanner that uses four different sensors and smart software to read heart health from the outside. It gives doctors the exact data they need to adjust treatment instantly, avoiding scary and invasive procedures.
Heart failure monitoring currently requires invasive procedures, meaning only a small percentage of patients receive optimal care. This leads to high readmission rates and massive healthcare spending.
A handheld electronic device (AHM) using four sensor types and machine learning to estimate intracardiac pressures non-invasively.
If you are a hospital dealing with 3 million annual heart failure hospitalizations in the EU — this project developed a handheld monitor that provides non-invasive pressure readings. This allows for faster treatment adjustments and reduces the frequency of patient readmissions.
If you are a distributor dealing with a lack of non-invasive hemodynamic tools — this project developed the AHM device based on a patented sensor system. It offers a first-of-its-kind tool for heart failure management that can be integrated into multiple clinical workflows.
If you are an insurer dealing with heart failure accounting for up to 5% of entire healthcare expenditure — this project developed a monitoring tool that improves patient prognosis. By reducing hospital admissions, it creates significant cost savings for the healthcare system.
Based on available project data, the specific unit price or cost of the AHM device is not disclosed.
The project is scaling from a 300-patient proof of concept to a multi-national study involving approximately 1250 patients across 14 sites to ensure the machine learning models are generalizable.
The technology is fully patent protected with three granted patent families and four patents pending, supplemented by proprietary datasets and a unique ML model.
The EIC support is specifically being used to develop and execute regulatory pathways to ensure market access once the project is finalized.
The project period runs from 2023-10-01 to 2025-05-31, with the goal of ensuring market access after the project concludes.
The project is led by a single Swedish SME, IAROCA AB, which holds 100% of the industry ratio. This lean structure suggests the company owns all the IP and is the sole driver of the commercialization strategy, utilizing EIC funding to move from a local proof-of-concept to a multi-national validation phase.
Contact IAROCA AB in Sweden for licensing and partnership inquiries.
Contact us to explore partnership opportunities with IAROCA AB for non-invasive cardiac monitoring.
